Regenerative peptides studied for angiogenesis, cell migration, and extracellular-matrix remodeling.
Healing and repair peptides are studied for their role in the cascade the body runs after tissue injury — recruiting blood supply, moving repair cells to the damage site, and rebuilding the structural matrix that holds tissue together. Unlike the metabolic class, much of this category rests on preclinical and mechanistic evidence rather than large human trials, so the research framing matters: these are reference profiles of investigational compounds, not validated therapies or dosing guidance.
Tissue repair is a staged process — hemostasis, inflammation, proliferation, and remodeling — and the peptides in this class are studied for their effects on the proliferation and remodeling phases in particular. The recurring theme is angiogenesis: re-establishing microvasculature so that oxygen and repair cells can reach hypoxic, damaged tissue. Compounds such as BPC-157 are studied for upregulation of the VEGF/VEGFR2 axis and nitric-oxide signaling in injured tendon, ligament, muscle, and gastrointestinal tissue.
A second mechanism is directed cell migration. Thymosin-β4-derived sequences (TB-500) act on the actin cytoskeleton — sequestering G-actin and modulating polymerization — which in preclinical models accelerates the movement of endothelial and progenitor cells into the wound bed. This is mechanistically distinct from angiogenic signaling but complementary to it, which is why these two peptides are frequently studied together in the literature.
The third axis is matrix remodeling and cytoprotection. Copper-binding peptides such as GHK-Cu are studied for modulation of collagen and elastin synthesis and a broad influence on extracellular-matrix and antioxidant gene programs. Other catalogued entries (LL-37, KPV) sit at the interface of repair and immune signaling — antimicrobial defense and resolution of inflammation are part of how a wound progresses to closure, so the healing and immune categories deliberately overlap.
Synthetic gastric pentadecapeptide investigated for tendon, ligament, and GI repair.
View profileSynthetic fragment of thymosin β4 studied for cell migration and tissue repair.
View profileA 27-residue single-chain relaxin-2 analog and selective RXFP1 agonist — a simplified relaxin mimetic studied for anti-fibrotic effects.
View profileEndogenous copper-binding tripeptide widely studied in skin and hair biology.
View profileA glycoprotein hormone that drives red-blood-cell production — a recombinant biologic famous in medicine for treating anemia and infamous in sport for blood doping.
View profileAn 11-amino-acid, non-erythropoietic fragment of erythropoietin that keeps EPO’s tissue-protective, anti-inflammatory activity without raising red blood cells.
View profileThe active fragment of parathyroid hormone — a recombinant peptide that builds bone, exploiting a paradox: the same hormone resorbs bone when continuous, but builds it when pulsed.
View profileSynthetic Ala-Glu-Asp-Arg tetrapeptide studied as a cardiac-tissue bioregulator.
View profileA natural cartilage and bone peptide complex (Cytomax A-4) from the Khavinson bioregulator line, marketed for joint and connective-tissue support.
View profileA natural skeletal-muscle peptide complex (Cytomax A-11) from the Khavinson bioregulator line, marketed for muscle-tissue support.
View profileHuman cathelicidin antimicrobial peptide active across bacteria, fungi, and viruses.
View profileAnti-inflammatory C-terminal tripeptide of α-MSH.
View profileIn this catalog, a healing/repair peptide is a peptide whose primary studied activity supports tissue regeneration — typically through angiogenesis, directed cell migration, or extracellular-matrix remodeling. Entries are reference profiles of investigational compounds, not products or treatment recommendations.
They act on different parts of the repair cascade. BPC-157 is studied primarily for pro-angiogenic and cytoprotective activity (VEGFR2 and nitric-oxide pathways), while TB-500 — a thymosin-β4 fragment — is studied for actin-cytoskeleton modulation that promotes cell migration to injury sites. They are mechanistically complementary, which is why the literature often examines them in parallel.
Evidence maturity varies widely and is generally earlier-stage than the metabolic class. Much of the supporting work is preclinical or mechanistic rather than large randomized human trials. This page reports studied mechanisms and research directions, not established clinical efficacy.
No. AmericanPeptide.com is a computational research and reference platform, not a medical device or clinical decision-support system. Nothing here is medical advice, a dosing protocol, or an offer to sell. Independent expert and regulatory review is required before any experimental use.